U.S. markets open in 1 hour 25 minutes

Cognition Therapeutics, Inc. (CGTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.6300-0.0800 (-4.68%)
At close: 04:00PM EDT
1.7500 +0.12 (+7.36%)
Pre-Market: 08:04AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close1.7100
Bid1.7500 x 1000
Ask2.7000 x 2200
Day's Range1.6200 - 1.8400
52 Week Range1.5000 - 13.8000
Avg. Volume525,463
Market Cap37.018M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.7990
Earnings DateMar 30, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CGTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cognition Therapeutics, Inc.
    Daily Spotlight: VIX Back to 30Fear has returned to the equity market, as inflation readings have failed to cool dramatically, the Federal Reserve remains on a long-term course toward higher rates, U.S. mid-term elections approach, Vladimir Putin threatens the use of nuclear weapons in Eastern Europe, and the global economy reels toward recession. The VIX Volatility Index is a key gauge of investor sentiment and has been elevated above 20 for most of the past two years. Last Friday, after a 486-point drop in the Dow Jones Industrial Average, the VIX closed at 29.92 after touching 32 earlier in the day. A little more than a month ago, the VIX was below 20, and seemingly headed lower as the U.S. consumer economy appeared to be in good shape. How can the market turn so quickly? Investors are always looking ahead, and the latest data (the CPI two weeks ago, the Fed's 75-basis-point hike last week) point toward near-term challenges for the economy, companies, and corporate earnings. New data will be out this week (the Fed's favorite inflation gauge, the PCE indices) and corporate earnings reports will start to flow in mid-October. We expect volatility to remain high, yet the pullback in stock prices unearths some attractive valuations. Buy low and sell high. We think investors should continue to focus on well-managed companies with clear growth objectives and clean balance sheets.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial

    PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to support completion of the ongoing SEQUEL Study of CT1812 in adults with mild-to-moderate Alzheimer’s disease. The aim of the SEQUEL trial is to investigate whether treatment with CT1812 results in a normalization of the EEG patterns, as

  • GlobeNewswire

    Cognition Therapeutics Announces Participation in September Investment Conferences

    PURCHASE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina, today announced that members of management will be participating in two investment conferences in September 2022. Details of the presentations are

  • Simply Wall St.

    We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...